Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 8/20 | 0.42 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 7/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6768409 | 1.00 | HSD17B2 (0.42) | HSD17B2CSNK2BCSNK2A1NAAAIDH1 | |
| SCHEMBL6771116 | 0.87 | HSD17B2 (0.43) | HSD17B2CSNK2BCSNK2A1NAAAIDH1 | |
| SCHEMBL15194999 | 0.79 | CSNK2B (0.34) | CSNK2BCSNK2A1NAAAIDH1FAAH | |
| SCHEMBL12152024 | 0.79 | CSNK2B (0.34) | CSNK2BCSNK2A1NAAAIDH1FAAH | |
| SCHEMBL6774487 | 0.73 | CSNK2B (0.36) | CSNK2BCSNK2A1NAAAIDH1FAAH | |
| SCHEMBL6768173 | 0.73 | CSNK2B (0.36) | CSNK2BCSNK2A1NAAAIDH1FAAH | |
| SCHEMBL14548187 | 0.72 | FAAH (0.45) | CSNK2BCSNK2A1NAAAIDH1FAAH | |
| SCHEMBL2501454 | 0.71 | NAAA (0.48) | NAAAIDH1FAAHPPARA | |
| SCHEMBL46356 | 0.71 | NAAA (0.48) | NAAAIDH1FAAHPPARA | |
| SCHEMBL2501460 | 0.71 | NAAA (0.48) | NAAAIDH1FAAHPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6784167-B2 | TREATING OSTEOPOROSIS, OSTEOPENIA, OVARIAN CANCER, BREAST CANCER, ENDOMETRIAL CANCER, ENDOMETRIOSIS, PROSTATE CANCER, ACNE, ANDROGEN-DEPENDENT HAIR LOSS, NON-INSULIN-DEPENDENT DIABETES MELLITUS, OR HYPERCHOLESTEROLEMIA. | BAYER PHARMACEUTICALS CORPORATION | 2004-08-31 | — | — | US | disclosed |
| EP-1326829-A2 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE-II INHIBITORS | Bayer Pharmaceuticals Corporation (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20030087952-A1 | 17-Beta-hydroxysteroid dehydrogenase-II inhibitors | BAYER PHARMACEUTICALS CORPORATION | 2003-05-08 | — | — | US | disclosed |
| WO-2002026706-A2 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE-II INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087952-A1 | 17-Beta-hydroxysteroid dehydrogenase-II inhibitors | HSD3B1, HSD3B2, HSD17B1 | HSD17B2 4/4885CSNK2B 826/4885CSNK2A1 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.